' x='0' y='0' width='795' height='447'%3E%3C/rect%3E%3Ctext id='Loading-Preview' font-family='AvenirNext-Bold, Avenir Next' font-size='42' font-weight='bold' fill='%23FFFFFF'%3E%3Ctspan x='228.715' y='211'%3ELoading Preview%3C/tspan%3E%3C/text%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Description | ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe. |
h1 tags | European SocietyFor Medical Oncology |
h2 tags | COVID-19 and Cancer June Virtual Plenary - Watch Now ESMO Congress 2021 Register Now: Localised Colon Cancer Webinar Where Will the Wave of Innovation Take Cancer Care? ESMO-Magnitude of Clinical Benefit Scale Latest News Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant Chemotherapy Adding Checkpoint Inhibition to Anti-HER2 Breast Cancer Therapy Brings no Benefit FDA Approves Avapritinib for Advanced Systemic Mastocytosis Efficacy and Safety of Patritumab Deruxtecan in EGFR-mutated NSCLC Resistant to EGFR TKI Therapy High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia APROMISS, SPEARHEAD-1 Trials Flag Synovial Sarcoma Therapy Advances FIGHT Study Update Supports FGFR2-Targeted Treatment For Gastric, Gastro-oesophageal Cancer Long-Term COLUMBUS Data Confirm Encorafenib–Binimetinib PFS Benefit in Advanced Melanoma Nivolumab–Ipilimumab Benefits Continue At 5 Years For Asymptomatic Brain Melanoma Metastases CHRONOS Trial Supports Metastatic CRC Liquid Biopsy-Guided EGFR Inhibitor Rechallenge Cabozantinib Shows ‘Potential’ For Radioiodine-Refractory Differentiated Thyroid Cancer Next Meetings IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line carboplatin and etoposide ± atezolizumab IMpassion050: A phase 3 study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy in high-risk, HER2-positive early breast cancer ESMO Virtual Advanced Course on EGFR-Mutated NSCLC 2021 ESMO Virtual Preceptorship on Gastroenteropancreatic and Lung Neuroendocrine Neoplasms 2021 ESMO Guidelines: Real World Cases - Webinar Series: Localised Colon Cancer ESMO Virtual Advanced Course on CAR-T and Next Generation Cell Therapies in Haematology and Solid Tumours 2021 ESMO Gynaecological Cancers Virtual Congress 2021 ECHNO-ICHNO 2021 Congress ESMO World Congress on Gastrointestinal Cancer 2021 ESMO-EANM Virtual Advanced Course on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology 2021 ESMO Academy Virtual Meeting 2021 ESMO Virtual Preceptorship on Cancer Care in Elderly Patients 2021 Video Gallery How to manage chemotherapy induced nausea and vomiting The challenge of lung cancer screening Efficacy of Cancer Screening: Evidences and Controversies Vaccinate cancer patients against COVID-19: experts address major uncertainties Expert Video Report on hematologic aspects of the Covid 19 pandemic from ASH 2020 What have we accomplished this year? ESMO Asia Virtual Congress 2020 Discover the ESMO Booth at ESMO Virtual Congress 2020 Prof. Fabrice André on new data presented at MAP 2020 Virtual Congress Prof. Fabrice André - Genomic profiling opening up new treatment possibilities for patients ESMO Virtual Congress 2020: anticipations on practice-changing results in gastric cancers ESMO Virtual Meeting 2020: anticipations on promising studies in lung cancer Education Provide your patients with the best care options. Meeting Resources ESMO Courses ESMO Oncology Journals Publications Career Development Improve your career path Are you looking for a fellowship not offered by ESMO or would like to post a fellowship? Maximise your potential and join the ESMO Young Oncologist Community Thinking of applying for an ESMO Oncology Fellowship? Become a Member |
Site Speed | 3.3956859111786 |
Alexa Rank: |
124780 |
Site's Traffic |
|
| Host | Type | Class | TTL | Target |
| esmo.org | SOA | IN | 3599 | |
| esmo.org | NS | IN | 3599 | ns1.virtualtec.ch |
| esmo.org | NS | IN | 3599 | ns2.virtualtec.ch |
| esmo.org | A | IN | 299 | |
| esmo.org | A | IN | 299 | |
| esmo.org | A | IN | 299 | |
| esmo.org | A | IN | 299 | |
| esmo.org | MX | IN | 3599 | esmo-org.mail.protection.outlook.com |
| esmo.org | TXT | IN | 3599 | |
| esmo.org | TXT | IN | 3599 | |
| esmo.org | TXT | IN | 3599 |